• 1
    Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995; 36: 18291.
  • 2
    Hageman GS, Anderson DH, Johnson LV et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 722732.
  • 3
    Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 3859.
  • 4
    Edwards AO, Ritter RR, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308: 4214.
  • 5
    Haines JL, Hauser MA, Schmidt S et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308: 41921.
  • 6
    Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007; 171: 71527.
  • 7
    Amara U, Rittirsch D, Flierl M et al. Interaction between the coagulation and complement system. Adv Exp Med Biol 2008; 632: 719.
  • 8
    Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004; 22: 43156.
  • 9
    Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med 1998; 188: 4318.
  • 10
    Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134: 41131.
  • 11
    van der Schaft TL, Mooy CM, de Bruijn WC, de Jong PT. Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol 1993; 77: 65761.
  • 12
    Mullins RF, Aptsiauri N, Hageman GS. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye (Lond) 2001; 15: 3905.
  • 13
    Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20: 70532.
  • 14
    Yates JR, Sepp T, Matharu BK et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357: 55361.
  • 15
    Gold B, Merriam JE, Zernant J et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006; 38: 45862.
  • 16
    Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004; 41: 35567.
  • 17
    Hageman GS, Hancox LS, Taiber AJ et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med 2006; 38: 592604.
  • 18
    Shuler RK, Schmidt S, Gallins P et al. Peripheral reticular pigmentary change is associated with complement factor H polymorphism (Y402H) in age-related macular degeneration. Ophthalmology 2008; 115: 5204.
  • 19
    Bora PS, Sohn JH, Cruz JM et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol 2005; 174: 4917.
  • 20
    Bora NS, Kaliappan S, Jha P et al. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol 2006; 177: 18728.
  • 21
    Jha P, Bora PS, Bora NS. The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol 2007; 44: 39018.
  • 22
    Anderson DH, Radeke MJ, Gallo NB et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010; 29: 95112.
  • 23
    Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc Natl Acad Sci USA 2006; 103: 1745661.
  • 24
    Robman L, Baird PN, Dimitrov PN, Richardson AJ, Guymer RH. C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology 2010; 117: 19828.
  • 25
    Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 143244.
  • 26
    Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 141931.
  • 27
    Nguyen QD, Shah SM, Hafiz G et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 113: 1522. e1-1522.e14.
  • 28
    Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 6678.
  • 29
    Wong WT, Kam W, Cunningham D et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Invest Ophthalmol Vis Sci 2010; 51: 61319.
  • 30
    Qin S, Rodrigues G. Progress and perspectives on the role of RPE cell inflammatory responses in the development of age-related macular degeneration. J Inflamm Res 2008; 1: 4965.
  • 31
    Do DV. Antiangiogenic approaches to age-related macular degeneration in the future. Ophthalmology 2009; 116: S246.
  • 32
    Tolentino MJ. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr Mol Med 2009; 9: 97381.
  • 33
    Ni Z, Hui P. Emerging pharmacologic therapies for wet age-related macular degeneration. Ophthalmologica 2009; 223: 40110.
  • 34
    Holland MC, Morikis D, Lambris JD. Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs 2004; 5: 116473.
  • 35
    Kaushal S, Grossi F, Francois C, Slakter J, ASaP Study Group. Complement C3 inhibitor POT-4: clinical safety of intravitreal administration. 2009. ARVO abstract – 5010 – A611.
  • 36
    Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2: 52.
  • 37
    Taube C, Thurman JM, Takeda K et al. Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation. Proc Natl Acad Sci USA 2006; 103: 80849.
  • 38
    Allegretti M, Moriconi A, Beccari AR et al. Targeting C5a: recent advances in drug discovery. Curr Med Chem 2005; 12: 21736.
  • 39
    Schnatbaum K, Locardi E, Scharn D et al. Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett 2006; 16: 508892.
  • 40
    Rohrer B, Long Q, Coughlin B et al. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci 2009; 50: 305664.
  • 41
    Wagenaar-Bos IG, Hack CE. Structure and function of C1-inhibitor. Immunol Allergy Clin North Am 2006; 26: 61532.
  • 42
    Mullins RF, Faidley EA, Daggett HT, Jomary C, Lotery AJ, Stone EM. Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes with age-related macular degeneration. Exp Eye Res 2009; 89: 76773.
  • 43
    Ennis S, Jomary C, Mullins R et al. Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study. Lancet 2008; 372: 182834.
  • 44
    Park KH, Ryu E, Tosakulwong N, Wu Y, Edwards AO. Common variation in the SERPING1 gene is not associated with age-related macular degeneration in two independent groups of subjects. Mol Vis 2009; 15: 2007.
  • 45
    Allikmets R, Dean M, Hageman GS et al. The SERPING1 gene and age-related macular degeneration. Lancet 2009; 374: 8756. author reply 876–7.
  • 46
    Ma K, Cashman S, Sweigard J, Kumar-Singh R. Decay accelerating factor (CD55) mediated attenuation of complement: therapeutic implications for age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51: 677683.
  • 47
    Guymer R, Robman L. Chlamydia pneumoniae and age-related macular degeneration: a role in pathogenesis or merely a chance association? Clin Experiment Ophthalmol 2007; 35: 8993.
  • 48
    Baird PN, Robman LD, Richardson AJ et al. Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet 2008; 17: 1299305.
  • 49
    Fujimoto T, Sonoda KH, Hijioka K et al. Choroidal neovascularization enhanced by Chlamydia pneumoniae via Toll-like receptor 2 in the retinal pigment epithelium. Invest Ophthalmol Vis Sci 2010; 51: 4694702.